Vermillion has appointed James LaFrance, chairman of the firms' board of directors, to succeed Thomas McLain as president and CEO.

LaFrance, who will continue to serve as Vermillion's board chairman, formerly was CEO of Omnyx. He also held executive leadership posts at Ventana Medical Systems and Bayer Diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.